DOCK2 and lung carcinoma: It is possible to detect the expression level of DOCK2 in patients with different oncological disorders, such as the high methylation of DOCK2 in lung cancer and prostate cancer, to further understand the mechanisms associated with the diseases and to provide new therapeutic targets for the treatment of the diseases.